• 9598 Citations
  • 53 h-Index
19992019
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where P. Lakatos is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 19 Similar Profiles
Inflammatory Bowel Diseases Medicine & Life Sciences
Crohn Disease Medicine & Life Sciences
Ulcerative Colitis Medicine & Life Sciences
Biosimilar Pharmaceuticals Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Hungary Medicine & Life Sciences
Population Medicine & Life Sciences
Biological Therapy Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2019

6 Citations (Scopus)

Biosimilars for the management of inflammatory bowel diseases: Economic considerations

Gulácsi, L., Pentek, M., Rencz, F., Brodszky, V., Baji, P., Vegh, Z., Gecse, K. B., Danese, S., Peyrin-Biroulet, L. & Lakatos, P., Jan 1 2019, In : Current medicinal chemistry. 26, 2, p. 259-269 11 p.

Research output: Contribution to journalArticle

Biosimilar Pharmaceuticals
Inflammatory Bowel Diseases
Economics
Budgets
Health

Biosimilars in IBD: Will it benefit to patients, physicians or the health care system?

Gonczi, L., Ilias, A., Kurti, Z. & Lakatos, P., Jan 1 2019, In : Current pharmaceutical design. 25, 1, p. 13-18 6 p.

Research output: Contribution to journalArticle

Biosimilar Pharmaceuticals
Ulcerative Colitis
Inflammatory Bowel Diseases
Crohn Disease
Cost-Benefit Analysis

Can We Say No to the 'Nocebo Effect' in Inflammatory Bowel Diseases?

Gonczi, L. & Lakatos, P., Sep 19 2019, In : Journal of Crohn's & colitis. 13, 9, p. 1095-1096 2 p.

Research output: Contribution to journalArticle

Nocebo Effect
Inflammatory Bowel Diseases